|
Phase II trial for hormone-refractory prostate cancer (HRPC)
TRIAL DESIGN
In this open label randomised trial, which includes crossover assignment (two consecutive treatments), TroVax will be assessed in combination with sanofi-aventis’ Taxotere® (docetaxel) as first line therapy versus docetaxel alone.
TRIAL OBJECTIVE
The primary endpoint will be safety and time to disease progression based on PSA (Prostate Specific Antigen) levels.
PATIENT POPULATION
Approximately 60 patients with progressive hormone refractory prostate cancer with no prior chemotherapy treatment are currently being recruited.
GET INVOLVED
Information on this clinical trial is available on www.clinicaltrials.gov.
LOCATION
This trial is being conducted by the Methodist Hospital, Houston, Texas.
Website by College Hill - Life Sciences
|
